{"content":"<li class=\"n-box-item date-title\" data-end=\"1496721599\" data-start=\"1496635200\" data-txt=\"Monday, December 23, 2019\">Monday, June  5, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3271711\" data-ts=\"1496706253\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEF\" target=\"_blank\">TEF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271711-report-telefonica-pondering-sale-of-mexico-unit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: Telefonica pondering sale of Mexico unit</a></h4><ul>   <li>Telefonica (<a href=\"http://seekingalpha.com/symbol/TEF\" target=\"_blank\">TEF</a> <font color='red'>-0.3%</font>) chief Jose Maria Alvarez-Pallete is considering getting rid of Telefonica Mexico under in-country expansion pressure from AT&amp;T (<a href=\"http://seekingalpha.com/symbol/T\" target=\"_blank\">T</a> <font color='red'>-0.2%</font>), according to <a href=\"https://translate.google.com/translate?hl=en&amp;sl=es&amp;u=http://www.vozpopuli.com/economia-y-finanzas/empresas/precios-ATT-Mexico-Slim-Telefonica_0_1032497149.html&amp;prev=search\" target=\"_blank\">news site Vozpopuli</a>.</li>    <li>Telefonica knows it faces a \"complicated\" situation, the report says, and could dispose of assets to get out of its position as the third operator (behind America Movil (<a href=\"http://seekingalpha.com/symbol/AMX\" target=\"_blank\">AMX</a> <font color='green'>+2.4%</font>) as well).</li>    <li>It still faces a debt burden of &euro;48.8B and is seeing worsening business amid AT&amp;T's push.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3271711\" data-linked=\"Report: Telefonica pondering sale of Mexico unit\" data-tweet=\"$TEF $TEF $T - Report: Telefonica pondering sale of Mexico unit https://seekingalpha.com/news/3271711-report-telefonica-pondering-sale-of-mexico-unit?source=tweet\" data-url=\"https://seekingalpha.com/news/3271711-report-telefonica-pondering-sale-of-mexico-unit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271710\" data-ts=\"1496705523\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/THC\" target=\"_blank\">THC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271710-tenet-healthcare-prices-notes-to-refinance-3_54b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tenet Healthcare prices notes to refinance $3.54B</a></h4><ul>   <li>Tenet Healthcare (<a href=\"http://seekingalpha.com/symbol/THC\" target=\"_blank\">THC</a> <font color='red'>-3.3%</font>) has <a href=\"https://seekingalpha.com/pr/16853010-tenet-announces-pricing-private-offering-senior-secured-unsecured-notes-refinance-3_541\" target=\"_blank\">priced a private offering of notes</a> it's issuing to refinance $3.541B.</li>    <li>The new tranches: $830M in senior secured first lien notes due 2024, at interest of 4.625%; $1.04B in senior secured first lien notes due 2024, at 4.625% interest (issued by THC Escrow Corp. III); 1.41B in senior secured second lien notes due 2025, at 5.125% (issued by THC Escrow Corp.); and $500M in senior unsecured notes due 2025, at 7% interest (issued by THC Escrow Corp.).</li>    <li>Proceeds will go to redeeming several series of notes due from 2018-2020.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3271710\" data-linked=\"Tenet Healthcare prices notes to refinance $3.54B\" data-tweet=\"$THC - Tenet Healthcare prices notes to refinance $3.54B https://seekingalpha.com/news/3271710-tenet-healthcare-prices-notes-to-refinance-3_54b?source=tweet\" data-url=\"https://seekingalpha.com/news/3271710-tenet-healthcare-prices-notes-to-refinance-3_54b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271706\" data-ts=\"1496703034\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIG\" target=\"_blank\">SIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271706-signet-jewelers-coo-resigns-after-violating-company-policy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Signet Jewelers COO resigns after violating company policy</a></h4><ul>     <li>Signet Jewelers (NYSE:<a href='https://seekingalpha.com/symbol/SIG' title='Signet Jewelers Limited'>SIG</a>) <font color='red'>-2.4%</font> AH after disclosing that COO Bryan Morgan <a href=\"https://seekingalpha.com/filing/3582126\" target=\"_blank\">resigned</a> because of \"violations of company policy unrelated to financial matters,\" with no further explanation provided.</li>     <li>Morgan had been COO and Executive VP of supply chain management since 2015 after holding positions of  increasing responsibility since joining the company in 2007.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271706\" data-linked=\"Signet Jewelers COO resigns after violating company policy\" data-tweet=\"$SIG - Signet Jewelers COO resigns after violating company policy https://seekingalpha.com/news/3271706-signet-jewelers-coo-resigns-after-violating-company-policy?source=tweet\" data-url=\"https://seekingalpha.com/news/3271706-signet-jewelers-coo-resigns-after-violating-company-policy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271705\" data-ts=\"1496702544\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CALL\" target=\"_blank\">CALL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271705-magicjack-vocaltecplus-16-on-report-of-yiptv-bid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MagicJack VocalTec +16% on report of YipTV bid</a></h4><ul>   <li>MagicJack VocalTec (NASDAQ:<a href='https://seekingalpha.com/symbol/CALL' title='magicJack VocalTec Communications Ltd.'>CALL</a>) <font color='green'>rose 15.9%</font> following a report from Axios that streaming provider YipTV has come in with a <a href=\"https://www.axios.com/exclusive-yip-tv-preps-takeover-offer-for-magicjack-2433630274.html\" target=\"_blank\">takeover bid</a>.</li>    <li>The Florida-based company is proposing a $9.50/share offer, the report says, a near-44% premium to yesterday's closing price for magicJack.</li>    <li>A source tells Axios that the smaller firm ($10M in expected 2017 revenue) has a $95M credit facility from Goldman Sachs to help it swallow magicJack, which recorded nearly $100M in revenue last year.</li>    <li>YipTV CEO Michael Tribolet once served as chief business officer for magicJack, Axios notes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3271705\" data-linked=\"MagicJack VocalTec +16% on report of YipTV bid\" data-tweet=\"$CALL - MagicJack VocalTec +16% on report of YipTV bid https://seekingalpha.com/news/3271705-magicjack-vocaltecplus-16-on-report-of-yiptv-bid?source=tweet\" data-url=\"https://seekingalpha.com/news/3271705-magicjack-vocaltecplus-16-on-report-of-yiptv-bid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271704\" data-ts=\"1496702519\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLDP\" target=\"_blank\">BLDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271704-ballard-wins-18m-follow-on-deal-to-support-400-buses-trucks-in-china\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ballard wins $18M follow-on deal to support 400 buses, trucks in China</a></h4><ul><li>Ballard Power (NASDAQ:<a href='https://seekingalpha.com/symbol/BLDP' title='Ballard Power Systems, Inc.'>BLDP</a>)&nbsp;<font color='green'>+3.7%</font> AH on news it was awarded an <a href=\"https://seekingalpha.com/pr/16852991-ballard-awarded-18m-follow-deal-broad-ocean-support-deployment-400-buses-trucks-china\" target=\"_blank\">$18M follow-on order</a>  with China's Zhongshan  Broad-Ocean Motor to support the deployment of 400 FCveloCity fuel cell  engines.</li><li>Combined with an $11M deal announced in  April, BLDP says it expects to support Broad-Ocean through  a total deployment of 600 fuel cell engines totaling $29M,  with substantial deliveries to be made this year.</li><li>BLDP says Broad-Ocean also plans to set up three module assembly operations in China,  representing another $25M to it over five years.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271704\" data-linked=\"Ballard wins $18M follow-on deal to support 400 buses, trucks in China\" data-tweet=\"$BLDP - Ballard wins $18M follow-on deal to support 400 buses, trucks in China https://seekingalpha.com/news/3271704-ballard-wins-18m-follow-on-deal-to-support-400-buses-trucks-in-china?source=tweet\" data-url=\"https://seekingalpha.com/news/3271704-ballard-wins-18m-follow-on-deal-to-support-400-buses-trucks-in-china\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271703\" data-ts=\"1496701057\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/THO\" target=\"_blank\">THO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271703-thor-industriesplus-11-earnings-show-strong-rv-demand\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Thor Industries +11% as earnings show strong RV demand</a></h4><ul><li>Thor Industries (NYSE:<a href='https://seekingalpha.com/symbol/THO' title='Thor Industries, Inc.'>THO</a>) <font color='green'>+10.6%</font>&nbsp;AH after <a href=\"https://seekingalpha.com/news/3271673-thor-beats-0_23-beats-revenue\" target=\"_blank\">FQ3 earnings</a> easily beat Wall Street expectations on record Q3 sales of $2B, driven by strong consumer demand.</li><li>THO says a decline in gross margins to 14.6% from 15.7% in the year-ago quarter was expected, due primarily to acquisition-related dilution and market-driven  changes  in product mix.</li><li>Consolidated RV backlogs more than doubled to  $2.36B from the year-ago quarter's $1.06B.</li><li>THO says it is continuing to expand  capacity, with new plants or expansion projects underway at nearly every subsidiary, which  will begin contributing to overall production capacity FQ4 and early in FY 2018.</li><li><a href=\"http://s21.q4cdn.com/991982067/files/doc_presentations/2017/ThorInvestorPresentation2017-06-05.pdf\" target=\"_blank\">Presentation</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3271703\" data-linked=\"Thor Industries +11% as earnings show strong RV demand\" data-tweet=\"$THO - Thor Industries +11% as earnings show strong RV demand https://seekingalpha.com/news/3271703-thor-industriesplus-11-earnings-show-strong-rv-demand?source=tweet\" data-url=\"https://seekingalpha.com/news/3271703-thor-industriesplus-11-earnings-show-strong-rv-demand\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271702\" data-ts=\"1496699806\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACOR\" target=\"_blank\">ACOR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271702-acorda-therapeuticsplus-8_5-on-positive-results-in-parkinsons-disease-drug\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acorda Therapeutics +8.5% on positive results in Parkinson&#39;s disease drug</a></h4><ul><li>Acorda Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACOR' title='Acorda Therapeutics, Inc.'>ACOR</a>)&nbsp;<font color='green'>+8.5%</font>&nbsp;AH after announcing that one of its Parkinson's disease drugs <a href=\"https://seekingalpha.com/pr/16852810-cvtminus-301-phase-3-data-showed-significantly-improved-motor-function-periods-parkinson-s\" target=\"_blank\">showed significant  improvements</a> to patients' motor functions during off periods.</li><li>ACOR says a phase 3  SPAN-PD study of CVT-301 (levodopa inhalation powder) met the primary endpoint of improvement in UPDRS III, supported by multiple secondary       endpoints, in data  presented today at the International Congress of Parkinson's Disease and Movement  Disorders.</li><li>ACOR says it plans to file a new drug application in the U.S. for CVT-301 by end of Q2.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271702\" data-linked=\"Acorda Therapeutics +8.5% on positive results in Parkinson&#39;s disease drug\" data-tweet=\"$ACOR - Acorda Therapeutics +8.5% on positive results in Parkinson&#39;s disease drug https://seekingalpha.com/news/3271702-acorda-therapeuticsplus-8_5-on-positive-results-in-parkinsons-disease-drug?source=tweet\" data-url=\"https://seekingalpha.com/news/3271702-acorda-therapeuticsplus-8_5-on-positive-results-in-parkinsons-disease-drug\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271699\" data-ts=\"1496698538\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271699-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/COVS' title='Covisint Corporation'>COVS</a> <font color='green'>+11.3%</font>. <a href='https://seekingalpha.com/symbol/THO' title='Thor Industries, Inc.'>THO</a> <font color='green'>+11.0%</font>. <a href='https://seekingalpha.com/symbol/ACOR' title='Acorda Therapeutics, Inc.'>ACOR</a> <font color='green'>+7.8%</font>. <a href='https://seekingalpha.com/symbol/REN' title='Resolute Energy Corporation'>REN</a> <font color='green'>+4.9%</font>. <a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a> <font color='green'>+3.7%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/CASY' title='Casey&#39;s General Stores, Inc.'>CASY</a> <font color='red'>-3.9%</font>. <a href='https://seekingalpha.com/symbol/PRGO' title='Perrigo Company'>PRGO</a> <font color='red'>-2.5%</font>. <a href='https://seekingalpha.com/symbol/SIG' title='Signet Jewelers Limited'>SIG</a> <font color='red'>-2.4%</font>. <a href='https://seekingalpha.com/symbol/OXM' title='Oxford Industries Inc.'>OXM</a> <font color='red'>-1.5%</font>. <a href='https://seekingalpha.com/symbol/NE' title='Noble Corporation plc'>NE</a> <font color='red'>-1.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3271699\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$COVS $THO $ACOR - After Hours Gainers / Losers https://seekingalpha.com/news/3271699-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3271699-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271691\" data-ts=\"1496696425\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WSM\" target=\"_blank\">WSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271691-j-crew-chief-drexler-moves-to-chairman-west-elms-brett-joins\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J. Crew chief Drexler moves to chairman; West Elm&#39;s Brett joins</a></h4><ul>    <li>Mickey Drexler, retailing veteran and CEO of J. Crew, will leave his chief executive post to <a href=\"https://seekingalpha.com/pr/16852918-jim-brett-joins-j-crew-chief-executive-officer\" target=\"_blank\">become chairman of the company</a>.</li>    <li>Jim Brett, president of West Elm (<a href=\"http://seekingalpha.com/symbol/WSM\" target=\"_blank\">WSM</a> <font color='red'>-3.8%</font>), will be J. Crew's new CEO starting in July. He'll join the J. Crew board as well.</li>    <li>Williams-Sonoma says Alex Bellos will <a href=\"https://seekingalpha.com/pr/16852919-williams-sonoma-inc-announces-west-elm-leadership-transition\" target=\"_blank\">succeed Brett</a>; Bellos has been head of the company's Rejuvenation and Mark and Graham brands.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3271691\" data-linked=\"J. Crew chief Drexler moves to chairman; West Elm&#39;s Brett joins\" data-tweet=\"$WSM - J. Crew chief Drexler moves to chairman; West Elm&#39;s Brett joins https://seekingalpha.com/news/3271691-j-crew-chief-drexler-moves-to-chairman-west-elms-brett-joins?source=tweet\" data-url=\"https://seekingalpha.com/news/3271691-j-crew-chief-drexler-moves-to-chairman-west-elms-brett-joins\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271689\" data-ts=\"1496696284\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALR\" target=\"_blank\">ALR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271689-alere-finally-files-2016-financials-top-line-down-3-loss-widened-to-1_83-shares-ahead-2-after\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alere finally files 2016 financials; top line down 3%, loss widened to ($1.83); shares ahead 2% after hours</a></h4><ul><li>Alere (NYSE:<a href='https://seekingalpha.com/symbol/ALR' title='Alere Inc.'>ALR</a>) <a href=\"https://seekingalpha.com/pr/16852909-alere-files-form-10-k-reports-fourth-quarter-full-year-2016-financial-results\" target=\"_blank\">files </a>its 2016 10-K after wrapping up its internal investigation into financial misstatements by its subsidiary in South Korea.</li><li>Q4 revenues were $597M (-3%) while loss/share was ($1.38).</li><li>For 2016, revenues were ~$2.4B (-3%) with loss/share of ($1.83).</li><li>All business segments were down yoy except Infectious Disease, up 9%.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;after hours on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271689\" data-linked=\"Alere finally files 2016 financials; top line down 3%, loss widened to ($1.83); shares ahead 2% after hours\" data-tweet=\"$ALR - Alere finally files 2016 financials; top line down 3%, loss widened to ($1.83); shares ahead 2% after hours https://seekingalpha.com/news/3271689-alere-finally-files-2016-financials-top-line-down-3-loss-widened-to-1_83-shares-ahead-2-after?source=tweet\" data-url=\"https://seekingalpha.com/news/3271689-alere-finally-files-2016-financials-top-line-down-3-loss-widened-to-1_83-shares-ahead-2-after\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271688\" data-ts=\"1496695727\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COUP\" target=\"_blank\">COUP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271688-coupa-software-beats-estimates-issues-strong-guidance-shares-up-1_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coupa Software beats estimates, issues strong guidance; shares up 1.8%</a></h4><ul><li>        Coupa Software (NASDAQ:<a href='https://seekingalpha.com/symbol/COUP' title='Coupa Software Inc'>COUP</a>) Q1 report beat EPS and revenue estimates.&nbsp; Subscription service revenues were $35.7M, a 41% increase on the prior year&rsquo;s quarter. Other key metrics include $238.1M in cash and cash equivalents, $88.6M in total deferred revenue, and $7.2M in cash from operating activities.</li><li>               Notable event: Coupa acquired Trade Extensions TradeExt AB for the company&rsquo;s supply chain optimization platform.&nbsp;</li><li>               Q2 guidance includes revenue of $41.3M-$41.8M, which comes in above the consensus estimate of $39.63M. Loss per share is expected between $0.18-$0.20, which straddles the consensus $0.19 loss.&nbsp;</li><li>               FY18 guidance includes $172M to $175M in revenue, above the $168.68M consensus, and loss per share of $0.49 to $0.53 compared to a consensus estimate of $0.52.&nbsp;</li><li>               Coupa Software shares are&nbsp;<font color='green'>up 1.84%</font>&nbsp;aftermarket.&nbsp;</li><li><a href=\"https://seekingalpha.com/pr/16852866-coupa-software-reports-financial-results-first-quarter-fiscal-2018\" target=\"_blank\">Press release</a> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3271676-coupa-software-beats-0_05-beats-revenue\" target=\"_blank\">Coupa Software beats by $0.05, beats on revenue</a> (June 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3271688\" data-linked=\"Coupa Software beats estimates, issues strong guidance; shares up 1.8%\" data-tweet=\"$COUP - Coupa Software beats estimates, issues strong guidance; shares up 1.8% https://seekingalpha.com/news/3271688-coupa-software-beats-estimates-issues-strong-guidance-shares-up-1_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3271688-coupa-software-beats-estimates-issues-strong-guidance-shares-up-1_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271687\" data-ts=\"1496695715\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INCY\" target=\"_blank\">INCY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271687-incytes-epacadostat-data-ok-barclays\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Incyte&#39;s epacadostat data OK - Barclays</a></h4><ul><li>Incyte (NASDAQ:<a href='https://seekingalpha.com/symbol/INCY' title='Incyte Corporation'>INCY</a>) is up a fraction after hours after slipping almost&nbsp;<font color='red'>6%</font>&nbsp;in the regular session. The sell-off was stoked by <a href=\"https://www.thestreet.com/story/14161896/1/missing-patients-cloud-view-of-incyte-s-ido-drug-lung-cancer-study.html\" target=\"_blank\">report </a>by TheStreet's Adam Feuerstein who noted that several patient responders were missing in the latest data on the combination epacadostat and Merck's Keytruda (pembrolizumab).</li><li>Barclays' Geoff Meacham says it is much ado about nothing since the patients in question had not had scans to assess anti-tumor activity after initial dosing. The patients are still on study.</li><li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3271451-combination-incytes-epacadostat-plus-mercks-ketyruda-demonstrates-activity-trial-patients\" target=\"_blank\">Combination of Incyte's epacadostat plus Merck's Ketyruda demonstrates activity in trial of patients with advanced non-small cell lung cancer</a> (June 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3271687\" data-linked=\"Incyte&#39;s epacadostat data OK - Barclays\" data-tweet=\"$INCY - Incyte&#39;s epacadostat data OK - Barclays https://seekingalpha.com/news/3271687-incytes-epacadostat-data-ok-barclays?source=tweet\" data-url=\"https://seekingalpha.com/news/3271687-incytes-epacadostat-data-ok-barclays\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271684\" data-ts=\"1496695503\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALR\" target=\"_blank\">ALR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271684-alere-eps-of-1_38\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alere EPS of -$1.38</a></h4><ul><li>Alere (NYSE:<a href='https://seekingalpha.com/symbol/ALR' title='Alere Inc.'>ALR</a>): Q4 EPS of -$1.38 may not be comparable to consensus of $0.48.</li><li>Revenue of $596.8M (-3.3% Y/Y) <font color='green'>beats by $8.66M</font>.</li><li>Shares <font color='green'>+2.5%</font>.</li><li><a href=\"https://seekingalpha.com/pr/16852909-alere-files-form-10-k-reports-fourth-quarter-full-year-2016-financial-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3271684\" data-linked=\"Alere EPS of -$1.38\" data-tweet=\"$ALR - Alere EPS of -$1.38 https://seekingalpha.com/news/3271684-alere-eps-of-1_38?source=tweet\" data-url=\"https://seekingalpha.com/news/3271684-alere-eps-of-1_38\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271682\" data-ts=\"1496695035\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCHP\" target=\"_blank\">MCHP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271682-microchip-technology-updates-guidance-for-fq1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microchip Technology updates guidance for FQ1</a></h4><ul>     <li>Microchip Technology (<a href='https://seekingalpha.com/symbol/MCHP' title='Microchip Technology Incorporated'>MCHP</a> <font color='green'>+0.2%</font>) <a href=\"https://seekingalpha.com/pr/16852877-microchip-technology-increases-guidance-net-sales-eps-first-quarter-fiscal-2018\" target=\"_blank\">now expects</a> consolidated net sales to be up 4.5% - 6% with a mid-point of up 5.25%.</li>     <li>Non-GAAP EPS expected to be between $1.22 - $1.26 vs. a consensus of $1.22 and prior guidance of $1.17 - $1.27.</li>     <li>The company expects GAAP EPS to be between $0.62 - $0.64 (prior $0.59 - $0.64).</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3271682\" data-linked=\"Microchip Technology updates guidance for FQ1\" data-tweet=\"$MCHP - Microchip Technology updates guidance for FQ1 https://seekingalpha.com/news/3271682-microchip-technology-updates-guidance-for-fq1?source=tweet\" data-url=\"https://seekingalpha.com/news/3271682-microchip-technology-updates-guidance-for-fq1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271675\" data-ts=\"1496693856\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLKS\" target=\"_blank\">FLKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271675-new-chief-flex-pharma-shares-slip-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New chief at Flex Pharma; shares slip 4% after hours</a></h4><ul><li>Flex Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/FLKS' title='Flex Pharma'>FLKS</a>) is flat after hours, albeit on only 100 shares, after the company <a href=\"https://seekingalpha.com/pr/16852843-flex-pharma-announces-executive-leadership-transition\" target=\"_blank\">announced</a> that CEO Christoph Westphal, M.D., Ph.D., will transition from his CEO role while remaining Chairman. President of R&amp;D William McVicar, Ph.D., will succeed his as interim CEO.</li><li>Dr. Westphal says the time is right for the move since the company is poised to initiate mid-stage clinical trials in the U.S.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271675\" data-linked=\"New chief at Flex Pharma; shares slip 4% after hours\" data-tweet=\"$FLKS $SLRX - New chief at Flex Pharma; shares slip 4% after hours https://seekingalpha.com/news/3271675-new-chief-flex-pharma-shares-slip-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3271675-new-chief-flex-pharma-shares-slip-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271673\" data-ts=\"1496693801\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/THO\" target=\"_blank\">THO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271673-thor-beats-0_23-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Thor beats by $0.23, beats on revenue</a></h4><ul><li>Thor (NYSE:<a href='https://seekingalpha.com/symbol/THO' title='Thor Industries, Inc.'>THO</a>): Q3 EPS of $2.11 <font color='green'>beats by $0.23</font>.</li><li>Revenue of $2.01B (+57.0% Y/Y) <font color='green'>beats by $50M</font>.</li><li>Shares <font color='green'>+4%</font>.</li><li><a href='https://seekingalpha.com/pr/16852858-thor-announces-record-results-third-quarter-first-nine-months-fiscal-2017'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3271673\" data-linked=\"Thor beats by $0.23, beats on revenue\" data-tweet=\"$THO - Thor beats by $0.23, beats on revenue https://seekingalpha.com/news/3271673-thor-beats-0_23-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3271673-thor-beats-0_23-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271667\" data-ts=\"1496693494\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTIC\" target=\"_blank\">CTIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271667-cti-biopharma-readies-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CTI BioPharma readies equity offering</a></h4><ul><li>CTI BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/CTIC' title='CTI BioPharma Corp.'>CTIC</a>) <a href=\"https://seekingalpha.com/pr/16852812-cti-biopharma-announces-proposed-public-offering-convertible-preferred-stock\" target=\"_blank\">announces </a>its intent to offer and sell shares of its Series N-3 Preferred Stock at $1,000 per share. Volume and terms have yet to be announced.</li><li>Net proceeds will fund the PAC203 clinical trial, the MAA submission in Europe for pacritinib, additional R&amp;D and working capital.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271667\" data-linked=\"CTI BioPharma readies equity offering\" data-tweet=\"$CTIC - CTI BioPharma readies equity offering https://seekingalpha.com/news/3271667-cti-biopharma-readies-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3271667-cti-biopharma-readies-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271658\" data-ts=\"1496692084\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANDV\" target=\"_blank\">ANDV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271658-tesoro-upped-to-buy-deutsche-bank-sharesplus-2_3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesoro upped to Buy at Deutsche Bank, shares +2.3%</a></h4><ul><li>Tesoro (TSO <font color='green'>+2.3%</font>) climbs to three-month highs as Deutsche Bank <a href=\"https://www.streetinsider.com/Analyst+Comments/Deutsche+Bank+Upgrades+Tesoro+Corporation+%28TSO%29+to+Buy/12978328.html\" target=\"_blank\">upgrades shares to Buy</a> from Hold with a $106 price target.</li><li>Despite the continued headwinds for the group, Deutsche Bank sees TSO as relatively well positioned, with one of the largest sum of the parts discounts of the peer group with potential 28%  upside to SOTP vs. 13% for peers.</li><li>The firm also sees multiple catalysts that should  provide an opportunity to narrow the discount, including the combination with Tesoro Logistics and Western Refining,  IDR restructuring, a $2B buyback program and portfolio optimization, while minimal RINs  exposure mitigates risk.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271658\" data-linked=\"Tesoro upped to Buy at Deutsche Bank, shares +2.3%\" data-tweet=\"$ANDV - Tesoro upped to Buy at Deutsche Bank, shares +2.3% https://seekingalpha.com/news/3271658-tesoro-upped-to-buy-deutsche-bank-sharesplus-2_3?source=tweet\" data-url=\"https://seekingalpha.com/news/3271658-tesoro-upped-to-buy-deutsche-bank-sharesplus-2_3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271656\" data-ts=\"1496691648\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMLS\" target=\"_blank\">CMLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271656-cumulus-mediaminus-11_2-sets-takeover-defense\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cumulus Media -11.2% as it sets takeover defense</a></h4><ul>   <li>Cumulus Media (NASDAQ:<a href='https://seekingalpha.com/symbol/CMLS' title='Cumulus Media Inc.'>CMLS</a>) is <font color='red'>off 11.2%</font> after announcing that its board has set up a rights agreement as an <a href=\"http://www.bizjournals.com/atlanta/news/2017/06/05/cumulus-media-adopts-anti-takeover-defense.html\" target=\"_blank\">anti-takeover defense</a>.</li>    <li>The rights will become exercisable if any person/group acquires a voting or economic position in 4.99% or more the company's Class A stock.</li>    <li>The stock's <font color='red'>lost 83% of its value</font> over the past year and its market cap is down to $13.8M; it owes $2.4B in debt.</li>    <li>It took on a new rights agreement to \"protect the Company&rsquo;s substantial net operating loss carryforwards in order to preserve the Company&rsquo;s long-term value and maintain the integrity of the Company&rsquo;s ongoing restructuring process.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3271656\" data-linked=\"Cumulus Media -11.2% as it sets takeover defense\" data-tweet=\"$CMLS - Cumulus Media -11.2% as it sets takeover defense https://seekingalpha.com/news/3271656-cumulus-mediaminus-11_2-sets-takeover-defense?source=tweet\" data-url=\"https://seekingalpha.com/news/3271656-cumulus-mediaminus-11_2-sets-takeover-defense\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271654\" data-ts=\"1496690832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLUE\" target=\"_blank\">BLUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271654-celgene-and-bluebirds-anti-bcma-car-t-candidate-shows-significant-treatment-effect-in-early\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celgene and bluebird&#39;s anti-BCMA CAR-T candidate shows significant treatment effect in early-stage multiple myeloma study; BLUE up 8%</a></h4><ul><li>Bluebird bio (<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a> <font color='green'>+8%</font>) and <a href=\"https://www.bluebirdbio.com/collaborations/\" target=\"_blank\">collaboration </a>partner Celgene (<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a> <font color='red'>-0.5%</font>) <a href=\"https://seekingalpha.com/pr/16851877-bluebird-bio-celgene-corporation-announce-updated-clinical-results-ongoing-first-human\" target=\"_blank\">announce </a>positive early-stage data on anti-BCMA CAR-T candidate bb2121 in patients with multiple myeloma. The results are being presented at ASCO.</li><li>Results from the Phase 1 study showed a 100% (n=15/15) objective response rate across all cohorts. No dose-limiting toxicities were observed.</li><li>The aim of the trial is to determine the recommended dose for a Phase 2 study.</li><li>Candidate bb2121 targets B-cell maturation antigen &#40;BCMA&#41;, a cell surface protein expressed in most multiple myeloma cells in addition to normal plasma cells.</li><li>Management will host a live webcast at 6:30 pm ET to discuss the results.</li><li>#ASCO17</li></ul><div class=\"tiny-share-widget\" data-id=\"3271654\" data-linked=\"Celgene and bluebird&#39;s anti-BCMA CAR-T candidate shows significant treatment effect in early-stage multiple myeloma study; BLUE up 8%\" data-tweet=\"$BLUE $BLUE $CELG - Celgene and bluebird&#39;s anti-BCMA CAR-T candidate shows significant treatment effect in early-stage multiple myeloma study; BLUE up 8% https://seekingalpha.com/news/3271654-celgene-and-bluebirds-anti-bcma-car-t-candidate-shows-significant-treatment-effect-in-early?source=tweet\" data-url=\"https://seekingalpha.com/news/3271654-celgene-and-bluebirds-anti-bcma-car-t-candidate-shows-significant-treatment-effect-in-early\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271649\" data-ts=\"1496689352\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDVX\" target=\"_blank\">MDVX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271649-medovex-denervex-cleared-in-europe-shares-down-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medovex DenerveX cleared in Europe; shares down 15%</a></h4><ul><li>Thinly traded nano cap Medovex (<a href='https://seekingalpha.com/symbol/MDVX' title='Medovex Inc.'>OTC:MDVX</a> <font color='red'>-15.1%</font>) is down on a 7x surge in volume despite the <a href=\"https://seekingalpha.com/pr/16852053-medovex-corporation-receives-ce-mark-approval-denervex-tm-system\" target=\"_blank\">good news</a> that its <a href=\"http://medovex.com/denervex_ous/\" target=\"_blank\">DenverveX System </a>is now CE Mark'd. The device denervates and removes capsular tissue from the Facet Joint (vertebral joint) in spinal procedures.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271649\" data-linked=\"Medovex DenerveX cleared in Europe; shares down 15%\" data-tweet=\"$MDVX $HCYT - Medovex DenerveX cleared in Europe; shares down 15% https://seekingalpha.com/news/3271649-medovex-denervex-cleared-in-europe-shares-down-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3271649-medovex-denervex-cleared-in-europe-shares-down-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271647\" data-ts=\"1496689203\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271647-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/CALL' title='magicJack VocalTec Communications Ltd.'>CALL</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/COVS' title='Covisint Corporation'>COVS</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/CNTF' title='China TechFaith Wireless Communication Technology Limited'>CNTF</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/SPCB' title='SuperCom, Ltd.'>SPCB</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CCIH' title='ChinaCache International'>CCIH</a> <font color='red'>-21%</font>. COGT <font color='red'>-17%</font>. DRAM <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/MRVC' title='MRV Communications, Inc.'>MRVC</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3271647\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$VHC $CALL $COVS - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3271647-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3271647-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271640\" data-ts=\"1496686418\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLNT\" target=\"_blank\">FLNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271640-cogintminus-17_7-short-piece-alleges-government-probes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cogint -17.7% as short piece alleges government probes</a></h4><ul>   <li>Cogint (COGT) has <font color='red'>slid 17.7%</font> today after an anonymous <a href=\"http://unemon.com/ResearchEasy/201706_COGT/20170605_COGT_Public.html\" target=\"_blank\">short seller piece</a> alleged multiple government investigations into collapsed stock promotions.</li>    <li>The seller, Une Mon, says documents reveal that several insiders (including Chairman Michael Brauser) are seeing scrutiny by the SEC and DOJ. The piece asserts a possible downside of 80-90% in share price toward an eventual delisting.</li>    <li><a href=\"https://seekingalpha.com/pr/16852627-cogint-responds-anonymous-short-seller-blog\" target=\"_blank\">Cogint has responded</a>: &ldquo;The blog contains numerous, recycled and fabricated inaccuracies and misstatements, solely, we believe, to serve the writer&rsquo;s interest of making money from the stock&rsquo;s decline,\" says CEO Derek Dubner.</li>    <li>\"As we have demonstrated for the last several quarters, our company is financially stronger, our business is solid, and we have built differentiated and valuable technology, massive databases, and products and solutions. The company and its management have not received any communications from the SEC or from any state, local, or federal law enforcement agency or any other regulatory body regarding the allegations in the blog.\"</li><li>Shares are <font color='green'>up 32%</font> YTD; share volume is running 14 times average today.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3271640\" data-linked=\"Cogint -17.7% as short piece alleges government probes\" data-tweet=\"$FLNT - Cogint -17.7% as short piece alleges government probes https://seekingalpha.com/news/3271640-cogintminus-17_7-short-piece-alleges-government-probes?source=tweet\" data-url=\"https://seekingalpha.com/news/3271640-cogintminus-17_7-short-piece-alleges-government-probes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271639\" data-ts=\"1496685671\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271639-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HOS' title='Hornbeck Offshore Services, Inc.'>HOS</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/FSI' title='Flexible Solutions International, Inc'>FSI</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/HLX' title='Helix Energy Solutions Group, Inc.'>HLX</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd'>NAK</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SNES' title='SenesTech'>SNES</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/WLB' title='Westmoreland Coal Co'>WLB</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corp'>LTBR</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/ESES' title='Eco-Stim Energy Solutions, Inc.'>ESES</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/UAN' title='CVR Partners, LP'>UAN</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271639\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$HOS $FSI $HLX - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3271639-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3271639-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271709\" data-ts=\"1496683565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USDP\" target=\"_blank\">USDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271709-usd-partners-to-expand-oklahoma-terminal-capacity-in-25m-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">USD Partners to expand Oklahoma terminal capacity in $25M deal</a></h4><ul><li>USD&nbsp;Partners (<a href='https://seekingalpha.com/symbol/USDP' title='USD Partners LP'>USDP</a> <font color='red'>-5.9%</font>) <a href=\"https://seekingalpha.com/pr/16851789-usd-partners-announces-acquisition-crude-oil-destination-terminal-stroud-oklahoma-new\" target=\"_blank\">agrees to acquire</a> a new crude oil terminal in Stroud, Okla., for $25M to facilitate rail-to-pipeline shipments of crude oil from its Hardisty terminal in western Canada to the Cushing,       Okla., crude oil hub.</li><li>As part of the deal, USDP enters into a new       multi-year, take-or-pay terminalling services agreement with an unnamed company for the use of ~50% of the Stroud terminal&rsquo;s       available capacity through June 2020.</li><li>The Stroud terminal includes 104 railcar  spots, two 70K-barrel storage tanks, a truck bay and a 17-mile pipeline directly connected to the Cushing  hub.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271709\" data-linked=\"USD Partners to expand Oklahoma terminal capacity in $25M deal\" data-tweet=\"$USDP - USD Partners to expand Oklahoma terminal capacity in $25M deal https://seekingalpha.com/news/3271709-usd-partners-to-expand-oklahoma-terminal-capacity-in-25m-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3271709-usd-partners-to-expand-oklahoma-terminal-capacity-in-25m-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271633\" data-ts=\"1496682874\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOX\" target=\"_blank\">BOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271633-box-shares-dive-amid-5_9m-share-block-trade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Box shares dive amid 5.9M share block trade</a></h4><ul><li>An investor sold 5.9M shares of enterprise storage company Box (NYSE:<a href='https://seekingalpha.com/symbol/BOX' title='Box'>BOX</a>)&nbsp;at a price of $19.07 to $19.37 per share, according to <a href=\"http://www.cnbc.com/2017/06/05/box-shares-drop-after-big-holder-dumps-the-stock.html\" target=\"_blank\">CNBC</a>. At the midpoint of the price range, the sale would value at around $113M.</li><li>Box shares are&nbsp;<font color='red'>down 4.26%.</font></li><li>Previously: <a href=\"https://seekingalpha.com/news/3270838-box-q1-beats-estimates-guidance-healthy-shares-3_5-percent\" target=\"_blank\">Box Q1 beats estimates, guidance healthy; shares up 3.5%</a> (May 31)</li></ul><div class=\"tiny-share-widget\" data-id=\"3271633\" data-linked=\"Box shares dive amid 5.9M share block trade\" data-tweet=\"$BOX - Box shares dive amid 5.9M share block trade https://seekingalpha.com/news/3271633-box-shares-dive-amid-5_9m-share-block-trade?source=tweet\" data-url=\"https://seekingalpha.com/news/3271633-box-shares-dive-amid-5_9m-share-block-trade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271622\" data-ts=\"1496682005\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271622-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FOR' title='Forestar Group Inc.'>FOR</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/YIN' title='Yintech Investment Holdings'>YIN</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MLP' title='Maui Land & Pineapple Company, Inc.'>MLP</a> <font color='red'>-6%</font>. WMIH <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271622\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$FOR $YIN $MLP - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3271622-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3271622-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271619\" data-ts=\"1496681177\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271619-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='green'>+59%</font>. <a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a> <font color='green'>+51%</font>. <a href='https://seekingalpha.com/symbol/NAKD' title='Naked Brand Group Limited'>NAKD</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/EVI' title='EnviroStar, Inc.'>EVI</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/FSI' title='Flexible Solutions International, Inc'>FSI</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/HOS' title='Hornbeck Offshore Services, Inc.'>HOS</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/TUES' title='Tuesday Morning Corp.'>TUES</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/HLX' title='Helix Energy Solutions Group, Inc.'>HLX</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc'>MBOT</a> <font color='red'>-30%</font>. COGT <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/CCIH' title='ChinaCache International'>CCIH</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/OMNT' title='Ominto, Inc.'>OTCPK:OMNT</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corp'>LTBR</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/MBVX' title='MABVAX THERAPEUTICS HLDGS'>OTCPK:MBVX</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/WLB' title='Westmoreland Coal Co'>WLB</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3271619\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$CLSN $LOXO $NAKD - Midday Gainers / Losers https://seekingalpha.com/news/3271619-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3271619-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271617\" data-ts=\"1496680791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CERN\" target=\"_blank\">CERN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271617-cerner-nabs-contract-va-to-develop-ehr-system-shares-ahead-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cerner nabs contract with VA to develop EHR system; shares ahead 1%</a></h4><ul><li>Cerner (<a href='https://seekingalpha.com/symbol/CERN' title='Cerner Corporation'>CERN</a> <font color='green'>+0.8%</font>) perks up on average volume in response to the <a href=\"http://www.bizjournals.com/kansascity/news/2017/06/05/veterans-affairs-selects-cerner-ehr-system.html?ana=twt\" target=\"_blank\">news </a>that it has been tapped by the U.S. Department of Veterans Affairs to develop an electronic health record &#40;EHR&#41; system to replace its legacy VistA system. Cerner says its offering will facilitate the exchange of data between military care facilities and civilian providers, where many service member receive care.</li><li>The size of the contract is not disclosed but it should be sizable considering the VA consists of 168 hospitals and 1,053 outpatient clinics that serve almost 9M veterans each year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271617\" data-linked=\"Cerner nabs contract with VA to develop EHR system; shares ahead 1%\" data-tweet=\"$CERN - Cerner nabs contract with VA to develop EHR system; shares ahead 1% https://seekingalpha.com/news/3271617-cerner-nabs-contract-va-to-develop-ehr-system-shares-ahead-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3271617-cerner-nabs-contract-va-to-develop-ehr-system-shares-ahead-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271604\" data-ts=\"1496678481\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271604-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NAKD' title='Naked Brand Group Limited'>NAKD</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/NAV' title='Navistar International Corporation'>NAV</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/MOD' title='Modine Manufacturing Company'>MOD</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VRS' title='Verso Corporation'>VRS</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/HLF' title='Herbalife Ltd.'>HLF</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/CENT' title='Central Garden & Pet Company'>CENT</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/TIS' title='Orchids Paper Products Company'>TIS</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SEED' title='Origin Agritech Limited'>SEED</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271604\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$NAKD $NAV $MOD - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3271604-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3271604-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271601\" data-ts=\"1496678261\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EKSO\" target=\"_blank\">EKSO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271601-ekso-cant-hold-on-to-premarket-gain-shares-off-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ekso can&#39;t hold on to premarket gain, shares off 10%</a></h4><ul><li>Ekso Bionics (<a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='red'>-9.9%</font>) looked like a winner in premarket trading but shares have turned south on more than double normal volume. This morning, the company <a href=\"https://seekingalpha.com/pr/16852016-ekso-bionics-develops-lightweight-flexible-exoskeleton-technology-expanding-technical-and\" target=\"_blank\">announced </a>that has completed development of a lightweight flexible-load exoskeleton prototype called Artemis.</li><li>The prototype weighs 13 pounds and can offload up to 75% of payload while being comfortable to wear. The company says its is exploring how to fit Artemis into its product development pipeline.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271601\" data-linked=\"Ekso can&#39;t hold on to premarket gain, shares off 10%\" data-tweet=\"$EKSO - Ekso can&#39;t hold on to premarket gain, shares off 10% https://seekingalpha.com/news/3271601-ekso-cant-hold-on-to-premarket-gain-shares-off-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3271601-ekso-cant-hold-on-to-premarket-gain-shares-off-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271593\" data-ts=\"1496676919\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VBLT\" target=\"_blank\">VBLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271593-vbls-ofranergene-obadenovec-shows-treatment-effect-in-mid-stage-brain-cancer-study-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VBL&#39;s ofranergene obadenovec shows treatment effect in mid-stage brain cancer study; shares slip 4%</a></h4><ul><li>Thinly traded micro cap VBL Therapeutics (<a href='https://seekingalpha.com/symbol/VBLT' title='VBL Therapeutics'>VBLT</a> <font color='red'>-3.6%</font>) eases on average volume despite <a href=\"https://seekingalpha.com/pr/16851887-new-phase-2-patient-data-presented-asco-strengthen-evidence-anti-tumor-activity-vbminus-111\" target=\"_blank\">announcing </a>positive Phase 2 data on VB-111 (ofranergene obadenovec) in recurrent glioblastoma. The results are being presented today at ASCO.</li><li>Overall survival at month 12 was 57% in the VB-111 continuous exposure cohort compared to 24% in historical pooled Avastin (bevacizumab) studies.</li><li>Enrollment (n=256) in a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02511405?term=vb-111&amp;rank=2\" target=\"_blank\">GLOBE</a>, was completed in December 2016. An interim analysis will be done next quarter with top-line results expected in early 2018. The primary endpoint is overall survival.</li><li>#ASCO17</li></ul><div class=\"tiny-share-widget\" data-id=\"3271593\" data-linked=\"VBL&#39;s ofranergene obadenovec shows treatment effect in mid-stage brain cancer study; shares slip 4%\" data-tweet=\"$VBLT - VBL&#39;s ofranergene obadenovec shows treatment effect in mid-stage brain cancer study; shares slip 4% https://seekingalpha.com/news/3271593-vbls-ofranergene-obadenovec-shows-treatment-effect-in-mid-stage-brain-cancer-study-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3271593-vbls-ofranergene-obadenovec-shows-treatment-effect-in-mid-stage-brain-cancer-study-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271595\" data-ts=\"1496676807\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAV\" target=\"_blank\">NAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271595-navistarplus-10-baird-upgrades-sees-transformed-company\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navistar +10% as Baird upgrades, sees transformed company</a></h4><ul><li>Navistar (<a href='https://seekingalpha.com/symbol/NAV' title='Navistar International Corporation'>NAV</a> <font color='green'>+10.3%</font>) shoots higher after Baird <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Baird+Upgrades+Navistar+International+%28NAV%29+to+Outperform/12976828.html\" target=\"_blank\">upgrades</a> shares to Outperform from Neutral with a $33 price target, up from $32, believing NAV is nearing the  end of a half-decade transformation after a near-fatal decision to  internally produce heavy-duty engines.</li><li>Baird also believes a transformed NAV is on the verge of driving higher volume, profit  margins and earnings that could take the stock above $50 during the next  several years.</li><li>The firm cites key catalysts as volumes and revenues, profit margins and cash flow, while risks include market share, financial leverage and timing, all of which are backstopped by Volkswagen's 17% position.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271595\" data-linked=\"Navistar +10% as Baird upgrades, sees transformed company\" data-tweet=\"$NAV - Navistar +10% as Baird upgrades, sees transformed company https://seekingalpha.com/news/3271595-navistarplus-10-baird-upgrades-sees-transformed-company?source=tweet\" data-url=\"https://seekingalpha.com/news/3271595-navistarplus-10-baird-upgrades-sees-transformed-company\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271589\" data-ts=\"1496675394\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNK\" target=\"_blank\">MNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271589-mallinckrodt-down-7-on-new-citron-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mallinckrodt down 7% on new Citron report</a></h4><ul><li>Mallinckrodt (<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a> <font color='red'>-7.4%</font>) slumps on a 40% spike in volume on the heels of a new <a href=\"http://www.citronresearch.com/wp-content/uploads/2017/06/MNK-and-EXPR-final-a.pdf\" target=\"_blank\">report </a>from short-seller Citron Research that says the company has been in cahoots with Express Scripts (<a href='https://seekingalpha.com/symbol/ESRX' title='Express Scripts, Inc.'>ESRX</a> <font color='green'>+0.1%</font>) to sell over-priced Acthar gel, but now the cat is out to bag after noted investor Jim Chanos described the relationship at the recent SALT conference.</li><li>Citron adds that ESRX has apparently reversed its position and will now be making a concerted effort to rein in the price of the medication.</li><li>Generic drug makers are also feeling MNK's pain. Almost all are down in early trading.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/ANIP' title='ANI Pharmaceuticals, Inc.'>ANIP</a> <font color='red'>-3.1%</font>)(<a href='https://seekingalpha.com/symbol/ACRS' title='Aclaris Therapeutics'>ACRS</a> <font color='red'>-2.1%</font>)(<a href='https://seekingalpha.com/symbol/RDY' title='Dr. Reddy&#39;s Laboratories Limited'>RDY</a> <font color='red'>-1.6%</font>)(<a href='https://seekingalpha.com/symbol/EGRX' title='Eagle Pharmaceuticals Inc.'>EGRX</a> <font color='red'>-0.6%</font>)(IPXL <font color='red'>-4.1%</font>)(<a href='https://seekingalpha.com/symbol/LCI' title='Lannett Company, Inc'>LCI</a> <font color='red'>-4%</font>)(<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='red'>-1.9%</font>)(<a href='https://seekingalpha.com/symbol/PRGO' title='Perrigo Company'>PRGO</a> <font color='red'>-5%</font>)(<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='red'>-0.7%</font>)(VRX <font color='red'>-4.3%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3271589\" data-linked=\"Mallinckrodt down 7% on new Citron report\" data-tweet=\"$MNK $MNK $ESRX - Mallinckrodt down 7% on new Citron report https://seekingalpha.com/news/3271589-mallinckrodt-down-7-on-new-citron-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3271589-mallinckrodt-down-7-on-new-citron-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271566\" data-ts=\"1496674842\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271566-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='green'>+72%</font>. <a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a> <font color='green'>+47%</font>. <a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/MLSS' title='Milestone Scientific Inc.'>MLSS</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc'>MBOT</a> <font color='red'>-29%</font>. <a href='https://seekingalpha.com/symbol/NEOS' title='Neos Therapeutics'>NEOS</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/ALDX' title='Aldeyra Therapeutics, Inc.'>ALDX</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271566\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$CLSN $LOXO $DVAX - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3271566-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3271566-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271583\" data-ts=\"1496674412\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZO\" target=\"_blank\">AZO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271583-ny-post-icahn-wants-to-buy-thousands-auto-repair-stores\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NY Post: Icahn wants to buy thousands more auto repair stores</a></h4><ul>     <li>AutoZone (<a href='https://seekingalpha.com/symbol/AZO' title='AutoZone, Inc'>AZO</a> <font color='red'>-1%</font>), O&rsquo;Reilly Automotive (<a href='https://seekingalpha.com/symbol/ORLY' title='O&#39;Reilly Automotive, Inc.'>ORLY</a> <font color='red'>-2.8%</font>) and Advance Auto Parts (<a href='https://seekingalpha.com/symbol/AAP' title='Advance Auto Parts, Inc.'>AAP</a> <font color='red'>-1.6%</font>) are lower following a <em>NY&nbsp;Post</em> report that Carl Icahn is <a href=\"http://nypost.com/2017/06/04/carl-icahn-plans-to-acquire-thousands-of-auto-repair-shops/\" target=\"_blank\">looking to buy thousands of auto repair shops</a>, with the idea that they will buy products directly from his own AutoPlus distributor instead of the national car parts chains.</li>     <li>Icahn&rsquo;s pitch is that the new arrangement would boost the profits of the repair shops that install auto parts, according to the report.</li><li>Icahn <a href=\"https://seekingalpha.com/pr/16850975-icahn-automotive-enters-definitive-agreement-acquire-precision-auto-care-inc\" target=\"_blank\">on Friday</a> announced the purchase of Precision Auto Care&rsquo;s 250  service locations, bringing the number of auto repair shops controlled by Icahn Automotive Group (<a href='https://seekingalpha.com/symbol/IEP' title='Icahn Enterprises L.P.'>IEP</a> <font color='red'>-0.5%</font>) to more than 1K, but he reportedly \"wants to do thousands&rdquo; more acquisitions of small- and medium-size repair and installation chains.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3271583\" data-linked=\"NY Post: Icahn wants to buy thousands more auto repair stores\" data-tweet=\"$AZO $AZO $ORLY - NY Post: Icahn wants to buy thousands more auto repair stores https://seekingalpha.com/news/3271583-ny-post-icahn-wants-to-buy-thousands-auto-repair-stores?source=tweet\" data-url=\"https://seekingalpha.com/news/3271583-ny-post-icahn-wants-to-buy-thousands-auto-repair-stores\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271574\" data-ts=\"1496672640\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBOT\" target=\"_blank\">MBOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271574-microbot-completes-round-trip-on-equity-offering-shares-down-28\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microbot completes round trip on equity offering; shares down 28%</a></h4><ul><li>Thinly traded nano cap Microbot Medical (<a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc'>MBOT</a> <font color='red'>-27.8%</font>) completes a round trip from last week's Canadian patent-stoked up move. This morning the company announced a <a href=\"https://seekingalpha.com/pr/16852302-microbot-medical-announces-10-million-registered-direct-offering-common-stock\" target=\"_blank\">direct placement</a> of 3.75M shares of common stock to three institutional investors yielding gross proceeds of $10.125M, implying a per-share price of $2.70. Proceeds will fund the expansion of the ViRob and TipCAT platforms, potential strategic partnerships and acquisition of assets, working capital and general corporate purposes.</li><li>Friday's close was $3.81.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271574\" data-linked=\"Microbot completes round trip on equity offering; shares down 28%\" data-tweet=\"$MBOT - Microbot completes round trip on equity offering; shares down 28% https://seekingalpha.com/news/3271574-microbot-completes-round-trip-on-equity-offering-shares-down-28?source=tweet\" data-url=\"https://seekingalpha.com/news/3271574-microbot-completes-round-trip-on-equity-offering-shares-down-28\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271567\" data-ts=\"1496671175\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPCB\" target=\"_blank\">SPCB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271567-supercom-q1-revenues-up-42-reiterates-guidance-shares-up-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SuperCom Q1 revenues up 42%, reiterates guidance; shares up 9%</a></h4><ul><li>        SuperCom (NASDAQ:<a href='https://seekingalpha.com/symbol/SPCB' title='SuperCom, Ltd.'>SPCB</a>) Q1 report included a revenue growth and loss per share. Other key metrics include 39.2% gross margin, EBITDA loss of $0.76M, and R&amp;D operating expenses of $1.7M.</li><li>               FY2017 guidance reiterated with revenue to surpass $35M, which would represent a 75% increase on the prior year.&nbsp;</li><li>SuperCom shares are&nbsp;<font color='green'>up 9%</font>.</li><li>               <a href=\"https://seekingalpha.com/pr/16852325-supercom-reports-42-percent-revenue-growth-first-quarter-2017-150-percent-improvement-gross\" target=\"_blank\">Press release</a>&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3271553-supercom-reports-q1-results\" target=\"_blank\">SuperCom reports Q1 results</a> (June 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3271567\" data-linked=\"SuperCom Q1 revenues up 42%, reiterates guidance; shares up 9%\" data-tweet=\"$SPCB - SuperCom Q1 revenues up 42%, reiterates guidance; shares up 9% https://seekingalpha.com/news/3271567-supercom-q1-revenues-up-42-reiterates-guidance-shares-up-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3271567-supercom-q1-revenues-up-42-reiterates-guidance-shares-up-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271565\" data-ts=\"1496670580\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WBMD\" target=\"_blank\">WBMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271565-webmdplus-3-after-report-iac-taking-look-purchase\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WebMD +3% after report IAC taking a look at purchase</a></h4><ul>   <li>WebMD (NASDAQ:<a href='https://seekingalpha.com/symbol/WBMD' title='WebMD Health Corp'>WBMD</a>) is <font color='green'>up 3%</font> amid word that IAC/InterActive Corp. (<a href='https://seekingalpha.com/symbol/IAC' title='IAC/InterActiveCorp'>IAC</a> <font color='red'>-0.3%</font>) is taking a look at bidding for the company, and that bidding looks to be topping $61/share, dealReporter notes.</li>    <li>WebMD is trading up to $58.60 today.</li>    <li>It's <font color='green'>up 18%</font> YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3271565\" data-linked=\"WebMD +3% after report IAC taking a look at purchase\" data-tweet=\"$WBMD $WBMD $IAC - WebMD +3% after report IAC taking a look at purchase https://seekingalpha.com/news/3271565-webmdplus-3-after-report-iac-taking-look-purchase?source=tweet\" data-url=\"https://seekingalpha.com/news/3271565-webmdplus-3-after-report-iac-taking-look-purchase\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271558\" data-ts=\"1496670416\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLSN\" target=\"_blank\">CLSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271558-celsions-genminus-1-shows-significant-treatment-effect-in-early-stage-ovarian-cancer-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celsion&#39;s GEN-1 shows significant treatment effect in early-stage ovarian cancer study; shares up 58%</a></h4><ul><li>Thinly traded nano cap Celsion (<a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='green'>+57.5%</font>) rockets up on almost triple normal volume, albeit on turnover of less than 300K shares, in response to its <a href=\"https://seekingalpha.com/pr/16852024-celsion-announces-presentation-ovation-study-findings-asco-2017-annual-meeting\" target=\"_blank\">announcement </a>of positive results from a Phase 1 clinical trial, OVATION, assessing its DNA-based immunotherapy candidate, GEN-1, in newly-diagnosed patients with advanced ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery. The data were presented as ASCO.</li><li>Treatment with GEN-1 produced a 100% (n=14/14) disease control rate, including two complete responders and 10 partial responders, implying an 86% (n=12/14) objective response rate &#40;ORR&#41;. The ORR in the highest dose cohort (n=5) was 100%.</li><li>GEN-1 stimulates the production of <a href=\"https://en.wikipedia.org/wiki/Interleukin_12\" target=\"_blank\">interleukin-12</a> (IL-12) in and around the tumor site. IL-12 stimulates the growth and function of cancer-fighting immune cells called CD8+ T lymphocytes and natural killer &#40;NK&#41; cells.</li><li>The company plans to evaluate GEN-1, in combination with Roche's Avastin (bevacizumab), in a second-line setting.</li><li>#ASCO17</li></ul><div class=\"tiny-share-widget\" data-id=\"3271558\" data-linked=\"Celsion&#39;s GEN-1 shows significant treatment effect in early-stage ovarian cancer study; shares up 58%\" data-tweet=\"$CLSN - Celsion&#39;s GEN-1 shows significant treatment effect in early-stage ovarian cancer study; shares up 58% https://seekingalpha.com/news/3271558-celsions-genminus-1-shows-significant-treatment-effect-in-early-stage-ovarian-cancer-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3271558-celsions-genminus-1-shows-significant-treatment-effect-in-early-stage-ovarian-cancer-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271555\" data-ts=\"1496669417\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/P\" target=\"_blank\">P</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271555-pandoraplus-2_7-on-word-of-possible-verizon-100m-investment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pandora +2.7% on word of possible Verizon $100M investment</a></h4><ul>   <li>Pandora Media (NYSE:<a href='https://seekingalpha.com/symbol/P' title='Pandora Media'>P</a>) is <font color='green'>up 2.7%</font> premarket after a <i>New York Post</i> report suggests that Verizon (NYSE:<a href='https://seekingalpha.com/symbol/VZ' title='Verizon Communications'>VZ</a>) may <a href=\"http://nypost.com/2017/06/04/verizon-mulling-pandora-investment-if-siriusxm-deal-fails/\" target=\"_blank\">invest up to $100M</a> in the streamer if it doesn't arrange its own outright sale to Sirius XM (NASDAQ:<a href='https://seekingalpha.com/symbol/SIRI' title='Sirius XM Holdings Inc.'>SIRI</a>).</li>    <li>But Verizon, no stranger to rumors of various outright takeovers lately, wouldn't buy Pandora in full since its busy working on Yahoo/AOL integration, sources told the <i>Post.</i></li>    <li>One scenario has Tim Armstrong joining the Pandora board, Claire Atkinson notes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3271555\" data-linked=\"Pandora +2.7% on word of possible Verizon $100M investment\" data-tweet=\"$P $P $VZ - Pandora +2.7% on word of possible Verizon $100M investment https://seekingalpha.com/news/3271555-pandoraplus-2_7-on-word-of-possible-verizon-100m-investment?source=tweet\" data-url=\"https://seekingalpha.com/news/3271555-pandoraplus-2_7-on-word-of-possible-verizon-100m-investment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271554\" data-ts=\"1496669362\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HLX\" target=\"_blank\">HLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271554-helix-energyplus-3-cowen-upgrades-to-outperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Helix Energy +3% as Cowen upgrades to Outperform</a></h4><ul>     <li>Helix Energy (NYSE:<a href='https://seekingalpha.com/symbol/HLX' title='Helix Energy Solutions Group, Inc.'>HLX</a>) <font color='green'>+3%</font> premarket after Cowen <a href=\"https://www.streetinsider.com/Analyst+Comments/Cowen+Upgrades+Helix+Energy+Solutions+Group%2C+Inc.+%28HLX%29+to+Outperform%2C+Top+Pick/12976900.html\" target=\"_blank\">upgrades</a> shares to Outperform from Market Perform with a $10 price target, up from $8, saying shares have been greatly de-risked with Siem Helix 1 now working and $320M in proceeds from equity.</li>     <li>The firm says HLX's stock price still implies a low case is  baked in, setting up an attractive risk-reward; its modeled EBITDA  through 2020 is mostly contracted, and HLX's net asset value suggests ~30% upside too, two  main differences compared with drillers.</li>     <li>Cowen also says vessel cancellation remains a low  probability risk for HLX.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3271554\" data-linked=\"Helix Energy +3% as Cowen upgrades to Outperform\" data-tweet=\"$HLX - Helix Energy +3% as Cowen upgrades to Outperform https://seekingalpha.com/news/3271554-helix-energyplus-3-cowen-upgrades-to-outperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3271554-helix-energyplus-3-cowen-upgrades-to-outperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271552\" data-ts=\"1496669259\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRRA\" target=\"_blank\">SRRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271552-sierra-oncologys-sra737-shows-encouraging-safety-characteristics-in-early-stage-stage-studies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sierra Oncology&#39;s SRA737 shows encouraging safety characteristics in early-stage stage studies; shares ahead 6% premarket</a></h4><ul><li>Thinly traded nano cap Sierra Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/SRRA' title='Sierra Oncology, Inc.'>SRRA</a>) perks up&nbsp;<font color='green'>6%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16851828-sierra-oncology-reports-encouraging-initial-progress-ongoing-phase-1-clinical-trials-chk1\" target=\"_blank\">announcement </a>of positive data from two Phase 1 clinical studies of Chk1 inhibitor SRA737. The results were presented as ASCO.</li><li>No dose-limiting toxicities have been observed and several cohorts have surpassed the minimum efficacious plasma concentration based on preclinical modeling.</li><li>The company intends to update investors on the studies, including preliminary activity data, in early 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271552\" data-linked=\"Sierra Oncology&#39;s SRA737 shows encouraging safety characteristics in early-stage stage studies; shares ahead 6% premarket\" data-tweet=\"$SRRA - Sierra Oncology&#39;s SRA737 shows encouraging safety characteristics in early-stage stage studies; shares ahead 6% premarket https://seekingalpha.com/news/3271552-sierra-oncologys-sra737-shows-encouraging-safety-characteristics-in-early-stage-stage-studies?source=tweet\" data-url=\"https://seekingalpha.com/news/3271552-sierra-oncologys-sra737-shows-encouraging-safety-characteristics-in-early-stage-stage-studies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271551\" data-ts=\"1496669132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271551-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a> <font color='green'>+41%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3271518-loxos-larotrectinib-shows-significant-treatment-effect-trk-fusion-cancers-shares-46-percent\" target=\"_blank\">showing</a> significant treatment effect in TRK fusion cancers.</li><li><a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='green'>+30%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16852024-celsion-announces-presentation-ovation-study-findings-asco-2017-annual-meeting\" target=\"_blank\">presentation</a> of OVATION study.</li><li><a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a> <font color='green'>+30%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3271528-dynavax-26-percent-premarket-positive-sdminus-101-results\" target=\"_blank\">positive</a> SD-101 results.</li><li><a href='https://seekingalpha.com/symbol/ONTX' title='Onconova Therapeutics'>ONTX</a> <font color='green'>+12%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16852130-onconova-therapeutics-announces-positive-phase-2-data-rigosertib-treated-patients-second-line\" target=\"_blank\">announcing</a> the results of a Phase 2 study with rigosertib as a treatment for higher risk (HR-MDS) after failure of hypomethylating agents.</li><li><a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a> <font color='green'>+12%</font>&nbsp;on announcing&nbsp;<a href=\"https://seekingalpha.com/news/3271532-tg-therapeutics-tgminus-1101-imbruvica-combo-successful-late-stage-cll-study-shares-ahead-13\" target=\"_blank\">positive results</a>&nbsp;in a Phase 3 clinical trial.</li><li><a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='green'>+11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3271452-puma-biotechnology-announces-positive-trial-results\" target=\"_blank\">announcing</a> positive trial results.</li><li><a href='https://seekingalpha.com/symbol/GIMO' title='Gigamon, Inc.'>GIMO</a> <font color='green'>+11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3271513-gigamon-ready-seek-buyers-shares-10-percent\" target=\"_blank\">ready</a> to seek buyers.</li><li><a href='https://seekingalpha.com/symbol/MDVX' title='Medovex Inc.'>OTC:MDVX</a> <font color='green'>+10%&nbsp;</font>on <a href=\"https://seekingalpha.com/pr/16852053-medovex-corporation-receives-ce-mark-approval-denervex-tm-system\" target=\"_blank\">receiving</a> CE Mark approval for the DenerveX&trade; System allowing the Company to market the DenerveX System in&nbsp;Europe.</li><li><a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+9%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16852281-mannkind-engages-locust-walk-explore-strategic-options-mannkind-s-non-insulin-technosphere\" target=\"_blank\">announcing</a> its decision to explore strategic and financial alternatives for MannKind&rsquo;s novel Technosphere-based pipeline candidates.</li><li><a href='https://seekingalpha.com/symbol/SRRA' title='Sierra Oncology, Inc.'>SRRA</a> <font color='green'>+7%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16851828-sierra-oncology-reports-encouraging-initial-progress-ongoing-phase-1-clinical-trials-chk1\" target=\"_blank\">initial progress</a> of the two ongoing Phase 1 trials of its Chk1 inhibitor, SRA737.</li><li><a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a> <font color='green'>+7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271551\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$LOXO $CLSN $DVAX - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3271551-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3271551-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271549\" data-ts=\"1496668637\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMY\" target=\"_blank\">BMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271549-bristol-myers-opdivo-yervoy-combo-shows-positive-effect-in-metastatic-melanoma-to-brain\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bristol-Myers&#39; Opdivo/Yervoy combo shows positive effect in metastatic melanoma to the brain, but with significant side effects including three deaths; shares ease 2% premarket</a></h4><ul><li>Despite a plethora of positive trial data presented at ASCO, Bristol-Myers Squibb (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>) is under early pressure in apparent response to <a href=\"https://seekingalpha.com/pr/16851621-first-presentation-efficacy-data-checkmate-minus-204-evaluating-combination-opdivo-nivolumab\" target=\"_blank\">results </a>from a mid-stage study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02320058?term=checkmate-204&amp;rank=1\" target=\"_blank\">CheckMate-204</a>, assessing the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) in patients with melanoma that has metastasized in the brain.</li><li>The overall response rate was impressive, 55%, including 21% complete responders, but grade 3 (serious) and grade 4 (life-threatening) side effects occurred in 52% (n=39) of participants. Six (8%) were neurologic, including headaches. Three treatment-related deaths were reported (cardiogenic shock, intracranial hemorrhage and malignant neoplasm progression).</li><li>#ASCO17</li></ul><div class=\"tiny-share-widget\" data-id=\"3271549\" data-linked=\"Bristol-Myers&#39; Opdivo/Yervoy combo shows positive effect in metastatic melanoma to the brain, but with significant side effects including three deaths; shares ease 2% premarket\" data-tweet=\"$BMY - Bristol-Myers&#39; Opdivo/Yervoy combo shows positive effect in metastatic melanoma to the brain, but with significant side effects including three deaths; shares ease 2% premarket https://seekingalpha.com/news/3271549-bristol-myers-opdivo-yervoy-combo-shows-positive-effect-in-metastatic-melanoma-to-brain?source=tweet\" data-url=\"https://seekingalpha.com/news/3271549-bristol-myers-opdivo-yervoy-combo-shows-positive-effect-in-metastatic-melanoma-to-brain\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271548\" data-ts=\"1496668598\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271548-snap-shares-down-2_6-jpmorgan-cuts-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap shares down 2.6% as JPMorgan cuts price target</a></h4><ul><li>        JPMorgan <a href=\"http://www.cnbc.com/2017/06/05/jpmorgan-cuts-snapchat-price-to-18.html\" target=\"_blank\">reduces</a> Snap&rsquo;s (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) price target from $20 to $18, citing concerns about the company&rsquo;s ability to monetize and scale its ad business and Snap&rsquo;s lack of profit.</li><li>               Other Snap concerns include competition from the likes of Facebook and the company&rsquo;s ability to continue adding new users.</li><li>               JPMorgan is conservative on the future of the smart sunglasses Spectacles, dropping its original projection of 915,000 units with $119M in sales this year down to 429,000 and $56M.&nbsp;&nbsp;</li><li>               The analyst note also noted that a share lock-up on June 29 could create volatility as 70% to 80% of shares become available for sale.&nbsp;</li><li>Snap shares are&nbsp;<font color='red'>down 2.61%</font>&nbsp;premarket. &nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3271548\" data-linked=\"Snap shares down 2.6% as JPMorgan cuts price target\" data-tweet=\"$SNAP - Snap shares down 2.6% as JPMorgan cuts price target https://seekingalpha.com/news/3271548-snap-shares-down-2_6-jpmorgan-cuts-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3271548-snap-shares-down-2_6-jpmorgan-cuts-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271547\" data-ts=\"1496668516\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPS\" target=\"_blank\">GPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271547-gap-up-1-after-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gap up more than 1% after upgrade</a></h4><ul><li>Oppenheimer analyst Anna Andreeva calls Street expectations for flat-to-down earnings this year \"too conservative\" after the company reported 12% EPS growth in Q1, with improved margins across all three brands.</li><li>Her SOTP analysts shows a value for Gap (NYSE:<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a>) of $28-$30 - this assumes no value to Banana Republic, and specialty retail multiples to the company's other brands.</li><li>She upgrades to Outperform and lifts the price target to $28 from $24.</li><li>Shares&nbsp;<font color='green'>+1.3%</font>&nbsp;premarket to $22.85.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271547\" data-linked=\"Gap up more than 1% after upgrade\" data-tweet=\"$GPS - Gap up more than 1% after upgrade https://seekingalpha.com/news/3271547-gap-up-1-after-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3271547-gap-up-1-after-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271546\" data-ts=\"1496668266\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271546-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc'>MBOT</a>&nbsp;<font color='red'>-16%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16852302-microbot-medical-announces-10-million-registered-direct-offering-common-stock\" target=\"_blank\">announcing</a> $10M direct offering of common stock.</li><li><a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a>&nbsp;<font color='red'>-7%</font>.</li><li><a href='https://seekingalpha.com/symbol/HLF' title='Herbalife Ltd.'>HLF</a>&nbsp;<font color='red'>-5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3271473-herbalife-ups-profit-cuts-sales-guidance\" target=\"_blank\">lowering</a> sales guidance.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3271546\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$MBOT $DRYS $HLF - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3271546-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3271546-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271537\" data-ts=\"1496667499\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRGO\" target=\"_blank\">PRGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271537-rbc-softens-view-on-perrigo-downgrades-to-underperform-shares-slip-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RBC softens view on Perrigo, downgrades to Underperform; shares slip 3% premarket</a></h4><ul><li>Perrigo (NASDAQ:<a href='https://seekingalpha.com/symbol/PRGO' title='Perrigo Company'>PRGO</a>) eases&nbsp;<font color='red'>3%</font>&nbsp;premarket on average volume on the heels of a <a href=\"https://www.streetinsider.com/Analyst+Comments/RBC+Capital+Downgrades+Perrigo+Co.+%28PRGO%29+to+Underperform%3B+Structural+headwinds+in+Consumer+adding+Rx+pressure/12976950.html\" target=\"_blank\">downgrade </a>to Underperform wit a $60 (18% downside risk) price target by RBC Capital Markets. Analyst Randall Stanicky cut his 2017 EPS estimate to $4.16 from $4.19 and 2018's to $4.75 from $5.11 citing structural headwinds in its consumer business.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271537\" data-linked=\"RBC softens view on Perrigo, downgrades to Underperform; shares slip 3% premarket\" data-tweet=\"$PRGO - RBC softens view on Perrigo, downgrades to Underperform; shares slip 3% premarket https://seekingalpha.com/news/3271537-rbc-softens-view-on-perrigo-downgrades-to-underperform-shares-slip-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3271537-rbc-softens-view-on-perrigo-downgrades-to-underperform-shares-slip-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271532\" data-ts=\"1496667041\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGTX\" target=\"_blank\">TGTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271532-tg-therapeutics-tgminus-1101-imbruvica-combo-successful-in-late-stage-cll-study-shares-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TG Therapeutics TG-1101/Imbruvica combo successful in late-stage CLL study; shares ahead 13% premarket</a></h4><ul><li>TG Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a>) is up&nbsp;<font color='green'>13%</font>&nbsp;premarket on robust volume in response to its announcement <a href=\"https://seekingalpha.com/pr/16851607-tg-therapeutics-announces-positive-data-phase-3-genuine-trial-tgminus-1101-combination\" target=\"_blank\">positive results</a> in a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02301156?term=NCT02301156&amp;rank=1\" target=\"_blank\">GENUINE</a>, assessing the combination of TG-1101 and AbbVie's (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) IMBRUVICA (ibrutinib) in patients with high-risk chronic lymphocytic leukemia &#40;CLL&#41;. The data were presented at ASCO.</li><li>The study met its primary endpoint of demonstrating a statistically significant improvement in overall response rate in patients receiving the combination compared to those treated with IMBRUVICA alone (78% vs. 45%; p&lt;0.001).</li><li>The company will host presentations today at 7:00 pm CT on the results.</li><li>#ASCO17</li><li>Previously: <a href=\"https://seekingalpha.com/news/3271383-tg-therapeutics-regaining-momentum-ahead-asco-data-presentation-shares-ahead-14-percent\" target=\"_blank\">TG Therapeutics regaining momentum ahead of ASCO data presentation; shares ahead 14%</a> (June 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3271532\" data-linked=\"TG Therapeutics TG-1101/Imbruvica combo successful in late-stage CLL study; shares ahead 13% premarket\" data-tweet=\"$TGTX $TGTX $ABBV - TG Therapeutics TG-1101/Imbruvica combo successful in late-stage CLL study; shares ahead 13% premarket https://seekingalpha.com/news/3271532-tg-therapeutics-tgminus-1101-imbruvica-combo-successful-in-late-stage-cll-study-shares-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3271532-tg-therapeutics-tgminus-1101-imbruvica-combo-successful-in-late-stage-cll-study-shares-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271535\" data-ts=\"1496666958\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JKS\" target=\"_blank\">JKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271535-jinkosolarminus-4-on-q1-earnings-miss-declining-margins\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JinkoSolar -4% on Q1 earnings miss, declining margins</a></h4><ul>     <li>JinkoSolar (NYSE:<a href='https://seekingalpha.com/symbol/JKS' title='JinkoSolar Holding Co., Ltd.'>JKS</a>) <font color='red'>-3.9%</font> premarket after reporting weaker than expected <a href=\"https://seekingalpha.com/news/3271488-jinkosolar-holding-misses-0_12-beats-revenue\" target=\"_blank\">Q1 earnings</a> and a 1% Y/Y drop in revenues.</li>     <li>JKS says Q1 gross margin was 11.2% compared with 14.3%  in Q4 2016 and 20.5% in Q1 2016, citing slightly lower average selling prices of solar modules, higher silicon prices and material costs caused by a supply shortage; the company expects improved margins in Q2 and H2  as its mono wafer and PERC cell capacity increases and polysilicon  prices stabilize.</li>     <li>Q1 solar module shipments totaled 2,068 MW, up 19.3% from 1,733 MW in Q4 and up 29.3% Y/Y from 1,600 MW.</li>     <li>JKS reaffirms FY 2017 guidance for total solar module shipments of 8.5-9.0 GW, and expects Q2 solar module shipments of 2.5-2.6 GW.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3271535\" data-linked=\"JinkoSolar -4% on Q1 earnings miss, declining margins\" data-tweet=\"$JKS - JinkoSolar -4% on Q1 earnings miss, declining margins https://seekingalpha.com/news/3271535-jinkosolarminus-4-on-q1-earnings-miss-declining-margins?source=tweet\" data-url=\"https://seekingalpha.com/news/3271535-jinkosolarminus-4-on-q1-earnings-miss-declining-margins\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271528\" data-ts=\"1496665995\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DVAX\" target=\"_blank\">DVAX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271528-dynavax-up-26-premarket-on-positive-sdminus-101-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dynavax up 26% premarket on positive SD-101 results</a></h4><ul><li>Dynavax Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a>) is up&nbsp;<font color='green'>26%</font>&nbsp;premarket on robust volume in response to its announcement of positive data on SD-101 and Merck's Keytruda in melanoma patients. The data were presented at ASCO.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3271405-combination-dynavaxs-sdminus-101-keytruda-show-100-percent-response-melanoma-study-shares\" target=\"_blank\">Combination of Dynavax's SD-101 and Keytruda show 100% response in melanoma study; shares ahead 4% after hours</a> (June 2)</li><li>#ASCO17</li></ul><div class=\"tiny-share-widget\" data-id=\"3271528\" data-linked=\"Dynavax up 26% premarket on positive SD-101 results\" data-tweet=\"$DVAX - Dynavax up 26% premarket on positive SD-101 results https://seekingalpha.com/news/3271528-dynavax-up-26-premarket-on-positive-sdminus-101-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3271528-dynavax-up-26-premarket-on-positive-sdminus-101-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271522\" data-ts=\"1496665809\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEOS\" target=\"_blank\">NEOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271522-neos-therapeutics-chief-technology-and-operations-officer-steps-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neos Therapeutics&#39; Chief Technology and Operations Officer steps down</a></h4><ul><li>Neos Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NEOS' title='Neos Therapeutics'>NEOS</a>) <a href=\"https://www.sec.gov/Archives/edgar/data/1467652/000110465917037350/a17-14685_28k.htm\" target=\"_blank\">announces</a> that Juergen A. Martens, the Chief Technology and Operations Officer will be resigning from his position effective June 30.</li><li><strong>Update</strong>: Shares are down&nbsp;<font color='red'>12%&nbsp;</font>in early trading on triple normal volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3271522\" data-linked=\"Neos Therapeutics&#39; Chief Technology and Operations Officer steps down\" data-tweet=\"$NEOS - Neos Therapeutics&#39; Chief Technology and Operations Officer steps down https://seekingalpha.com/news/3271522-neos-therapeutics-chief-technology-and-operations-officer-steps-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3271522-neos-therapeutics-chief-technology-and-operations-officer-steps-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271520\" data-ts=\"1496665273\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPX\" target=\"_blank\">TPX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271520-tempur-sealyplus-1_5-on-strong-order-numbers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tempur Sealy +1.5% on strong order numbers</a></h4><ul><li>The <a href=\"https://seekingalpha.com/pr/16852000-tempur-sealy-provides-business-update\" target=\"_blank\">company says </a>North America orders in May rose 15% Y/Y (excl. Mattress Firm). Tempur-Pedic branded product orders were up 28%.</li><li>Combining April and May, North America orders (excl. Mattress Firm) were up 7% Y/Y - negatively impacted in April by a&nbsp;large liquidation event of Tempur Sealy branded inventory by Mattress Firm.</li><li><a href='https://seekingalpha.com/symbol/TPX' title='Tempur Sealy International Inc.'>TPX</a>&nbsp;<font color='green'>+1.5%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3271520\" data-linked=\"Tempur Sealy +1.5% on strong order numbers\" data-tweet=\"$TPX - Tempur Sealy +1.5% on strong order numbers https://seekingalpha.com/news/3271520-tempur-sealyplus-1_5-on-strong-order-numbers?source=tweet\" data-url=\"https://seekingalpha.com/news/3271520-tempur-sealyplus-1_5-on-strong-order-numbers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271519\" data-ts=\"1496665080\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YELP\" target=\"_blank\">YELP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271519-bank-of-america-merrill-lynch-upgrades-yelp-shares-up-2_6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bank of America Merrill Lynch upgrades Yelp; shares up 2.6%</a></h4><ul><li>        Bank of America Merrill Lynch upgrades Yelp (NYSE:<a href='https://seekingalpha.com/symbol/YELP' title='Yelp'>YELP</a>) from Neutral to Buy.</li><li>               In a note, analyst Justin Post cites the easy growth churn comps in the second quarter and expects things to get even easier by the fourth quarter.&nbsp;</li><li>               Post says that Yelp could better execute to push multiple closer to competitors but noted that the stock is currently trading at 10x EV/EBITDA versus Yelp&rsquo;s average of 18x and the 14x average of competitors or peers.&nbsp;</li><li>               Price target: $37.&nbsp;</li><li>Source: Bloomberg. </li><li>Yelp shares are&nbsp;<font color='green'>up 2.64%</font>&nbsp;premarket. &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3271519\" data-linked=\"Bank of America Merrill Lynch upgrades Yelp; shares up 2.6%\" data-tweet=\"$YELP - Bank of America Merrill Lynch upgrades Yelp; shares up 2.6% https://seekingalpha.com/news/3271519-bank-of-america-merrill-lynch-upgrades-yelp-shares-up-2_6?source=tweet\" data-url=\"https://seekingalpha.com/news/3271519-bank-of-america-merrill-lynch-upgrades-yelp-shares-up-2_6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271514\" data-ts=\"1496664261\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RHHBY\" target=\"_blank\">RHHBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271514-roche-stumbles-perjeta-cocktail-in-breast-cancer-barely-beating-herceptin-and-chemo-in-late\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roche stumbles with Perjeta cocktail in breast cancer, barely beating Herceptin and chemo in late-stage study; rival Puma Biotech up 18% premarket</a></h4><ul><li>Roche's (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>) effort to protect its $7B breast cancer business has hit a bump in the road with <a href=\"http://www.roche.com/media/store/releases/med-cor-2017-06-05.htm\" target=\"_blank\">disappointing results</a> in a long-term Phase 3 clinical trial, APHINITY, comparing a cocktail of Perjeta (pertuzumab), Herceptin (trastuzumab) and chemo to Herceptin and chemo only. The data were presented as ASCO.</li><li>At year three, 94.1% of patients treated with the Perjeta-based regimen did not have their cancer return, barely above 93.2% for Herceptin + chemo. An estimate of invasive disease-free survival (iDFS) at four years showed 92.3% of patients receiving the Perjeta regimen did not have a cancer recurrence compared to 90.6% for Herceptin + chemo.</li><li>The company is trying to establish a new moat around its breast cancer franchise since Herceptin faces biosimilar competition. The small difference in treatment effect makes the rationale for the more-expensive Perjeta approach <a href=\"https://www.ft.com/content/2b87ecbc-4999-11e7-919a-1e14ce4af89b\" target=\"_blank\">more difficult to defend</a> (Perjeta and Herceptin each cost ~$70K/year).</li><li>Puma Biotechnology (NYSE:<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a>) is up&nbsp;<font color='green'>18%</font>&nbsp;premarket in increased volume as investors perceive improved prospects for breast cancer candidate PB272.</li><li>#ASCO17</li></ul><div class=\"tiny-share-widget\" data-id=\"3271514\" data-linked=\"Roche stumbles with Perjeta cocktail in breast cancer, barely beating Herceptin and chemo in late-stage study; rival Puma Biotech up 18% premarket\" data-tweet=\"$RHHBY $RHHBY $PBYI - Roche stumbles with Perjeta cocktail in breast cancer, barely beating Herceptin and chemo in late-stage study; rival Puma Biotech up 18% premarket https://seekingalpha.com/news/3271514-roche-stumbles-perjeta-cocktail-in-breast-cancer-barely-beating-herceptin-and-chemo-in-late?source=tweet\" data-url=\"https://seekingalpha.com/news/3271514-roche-stumbles-perjeta-cocktail-in-breast-cancer-barely-beating-herceptin-and-chemo-in-late\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271513\" data-ts=\"1496664233\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIMO\" target=\"_blank\">GIMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271513-gigamon-ready-to-seek-buyers-shares-up-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gigamon ready to seek buyers; shares up 10%</a></h4><ul><li>        Network monitoring software company Gigamon Inc (NYSE:<a href='https://seekingalpha.com/symbol/GIMO' title='Gigamon, Inc.'>GIMO</a>) is ready to hold talks with potential buyers, according to <a href=\"https://www.reuters.com/article/us-gigamon-m-a-exclusive-idUSKBN18T31J\" target=\"_blank\">Reuters</a>.</li><li>               Activist hedge fund Elliott Management Corp acquired a 15.3% stake last month and encouraged Gigamon to undergo a strategic review with a potential sale.&nbsp;</li><li>               The sale process, guided by Goldman Sachs Group, hasn&rsquo;t formally started yet. Bidders might include the likes of Hewlett Packard Enterprise or a tech-focused private equity firm.&nbsp;</li><li>                  Gigamon shares are&nbsp;<font color='green'>up 10%</font>&nbsp;premarket.&nbsp;   &nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3271513\" data-linked=\"Gigamon ready to seek buyers; shares up 10%\" data-tweet=\"$GIMO - Gigamon ready to seek buyers; shares up 10% https://seekingalpha.com/news/3271513-gigamon-ready-to-seek-buyers-shares-up-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3271513-gigamon-ready-to-seek-buyers-shares-up-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271502\" data-ts=\"1496661769\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYTR\" target=\"_blank\">CYTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271502-cytrx-set-for-down-day-on-disappointing-os-data-on-aldoxorubicin-shares-slip-11-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CytRx set for down day on disappointing OS data on aldoxorubicin; shares slip 11% premarket</a></h4><ul><li>CytRx (NASDAQ:<a href='https://seekingalpha.com/symbol/CYTR' title='CytRx Corporation'>CYTR</a>) eases&nbsp;<font color='red'>11%</font>&nbsp;premarket on light volume. On Friday afternoon at ASCO, Phase 3 data were presented on aldoxorubicin in soft tissue sarcoma (Abstract #11000). Treatment extended median progression-free survival but there was <a href=\"https://twitter.com/adamfeuerstein/status/871686213849272320\" target=\"_blank\">no difference</a>&nbsp;in overall survival compared to investigators' choice of therapy.</li><li>The data were contained in a slide presented at ASCO and reported (Twitter) by Adam Feuerstein.</li><li>Data presentation</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3268474-late-stage-data-cytrxs-aldoxorubicin-sts-showed-treatment-benefit-shares-14-percent\" target=\"_blank\">Late-stage data on CytRx's aldoxorubicin in STS showed treatment benefit; shares up 14%</a> (May 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3271502\" data-linked=\"CytRx set for down day on disappointing OS data on aldoxorubicin; shares slip 11% premarket\" data-tweet=\"$CYTR - CytRx set for down day on disappointing OS data on aldoxorubicin; shares slip 11% premarket https://seekingalpha.com/news/3271502-cytrx-set-for-down-day-on-disappointing-os-data-on-aldoxorubicin-shares-slip-11-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3271502-cytrx-set-for-down-day-on-disappointing-os-data-on-aldoxorubicin-shares-slip-11-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>103&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271499\" data-ts=\"1496660756\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DHI\" target=\"_blank\">DHI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271499-forestar-group-up-13-d-r-horton-bids-for-controlling-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Forestar Group up 13% as D.R. Horton bids for controlling stake</a></h4><ul><li>D.R. Horton (NYSE:<a href='https://seekingalpha.com/symbol/DHI' title='D. R. Horton Inc.'>DHI</a>) offers to <a href=\"https://seekingalpha.com/pr/16851760-d-r-horton-inc-proposes-acquire-75-percent-forestar-group-inc-16_25-per-share-cash\" target=\"_blank\">purchase 75% of </a>Forestar Group (NYSE:<a href='https://seekingalpha.com/symbol/FOR' title='Forestar Group Inc.'>FOR</a>) for $16.25 per share in cash, a 14% premium to Forestar's current merger deal with Starwood Capital.</li><li>Under the D.R. Horton proposal, Forestar would remain a public company, and its shareholders thus able to participate in what DHI believes would be significant value creation through the two companies' strategic relationship.</li><li>D.R. Horton would have Forestar led by Donald Tomnitz, who was DHI's CEO for 15 years.</li><li>A <a href=\"http://investor.drhorton.com\" target=\"_blank\">conference call </a>is set for 8:30 ET.</li><li><a href=\"http://investor.drhorton.com/FOR\" target=\"_blank\">Presentation slides</a></li><li>FOR<font color='green'> +13%</font>&nbsp;premarket to $16.05</li></ul><div class=\"tiny-share-widget\" data-id=\"3271499\" data-linked=\"Forestar Group up 13% as D.R. Horton bids for controlling stake\" data-tweet=\"$DHI $DHI $FOR - Forestar Group up 13% as D.R. Horton bids for controlling stake https://seekingalpha.com/news/3271499-forestar-group-up-13-d-r-horton-bids-for-controlling-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3271499-forestar-group-up-13-d-r-horton-bids-for-controlling-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3271492\" data-ts=\"1496659781\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EHIC\" target=\"_blank\">EHIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3271492-ehi-car-services-positive-post-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">eHi Car Services positive post Q1 results</a></h4><ul>     <li>eHi Car Services&nbsp;(NYSE:<a href='https://seekingalpha.com/symbol/EHIC' title='eHi Car Services'>EHIC</a>) reports Car rentals revenues rose 36.5% to RMB496.68M in <a href=\"https://seekingalpha.com/pr/16851735-ehi-car-services-announces-first-quarter-2017-results\" target=\"_blank\">Q1</a>.</li>     <li>Car services revenues increased 23.2% to RMB118.9M.</li>     <li>RevPAC for the quarter grew 2% to 152.</li>     <li>Gross margin rate improved 300 bps&nbsp;due to a percentage decrease of vehicle-related depreciation in terms of net revenues.</li>     <li>Adjusted EBIT margin rate expanded 350 bps to 15.4%.</li>     <li>The company expects Q2 revenue to be in the range of RMB635M to RMB650M and for FY2017 to be in &nbsp;the range of RMB2.9B to RMB3B.</li>     <li>EHIC&nbsp;<font color='green'>+1.88%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3271492\" data-linked=\"eHi Car Services positive post Q1 results\" data-tweet=\"$EHIC - eHi Car Services positive post Q1 results https://seekingalpha.com/news/3271492-ehi-car-services-positive-post-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3271492-ehi-car-services-positive-post-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:49 AM </div></div></li>","count":60,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}